May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Protection of Retinal Ganglion Cells in Aging DBA/2J Mice by 17-beta-Estradiol via Activation of Akt/CREB/Thioredoxin and Inhibition of MAPK/NF-kB Cascades
Author Affiliations & Notes
  • X. Zhou
    Ophthalmology, Univ of Oklahoma Hlth Sci Ctr, Oklahoma City, Oklahoma
  • S. R. Sarkisian, Jr.
    Ophthalmology, Univ of Oklahoma Hlth Sci Ctr, Oklahoma City, Oklahoma
  • J. Chodosh
    Ophthalmology, Univ of Oklahoma Hlth Sci Ctr, Oklahoma City, Oklahoma
  • W. Cao
    Ophthalmology, Univ of Oklahoma Hlth Sci Ctr, Oklahoma City, Oklahoma
  • Footnotes
    Commercial Relationships X. Zhou, None; S.R. Sarkisian, None; J. Chodosh, None; W. Cao, None.
  • Footnotes
    Support Foundation Fighting Blindness (FFB), and NIH grant P20 RR017703 from COBRE, and an unrestricted grant from RPB to the Dept. of Ophthal., OUHSC, and a NIH core grant EY12190, and OCAST Grant HR06-012.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 4919. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      X. Zhou, S. R. Sarkisian, Jr., J. Chodosh, W. Cao; Protection of Retinal Ganglion Cells in Aging DBA/2J Mice by 17-beta-Estradiol via Activation of Akt/CREB/Thioredoxin and Inhibition of MAPK/NF-kB Cascades. Invest. Ophthalmol. Vis. Sci. 2007;48(13):4919.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: Aging DBA/2J mice develop progressive eye abnormalities that closely mimic human pigmentary glaucoma. The onset of the disease symptoms in these mice begins between 3 and 4 months of age and affects 56% of the female mice while only 15% of the males show symptoms. These symptoms include signs of iris pigment epithelium loss and transillumination of the peripheral iris. By 9 months of age, female DBA/2J mice exhibit higher intraocular pressure (IOP) than males (www.jax.org). Several lines of evidence indicate that estrogen has neurotrophic and neuroprotective properties. Neuroprotection of retinal ganglion cells (RGC) becomes an important approach of glaucoma therapy. In this study, we examine the role of estrogen in the delay of disease progression and in the RGC protection in DBA/2J mice.

Methods:: Female DBA/2J mice at two months old were anesthetized and ovariectomized with or without subcutaneous 17-beta-estradiol pellet implantation. RGC survival was evaluated from flat-mounted retina by counting retrograde labeled cells. The loss of nerve fiber and RGC were also evaluated quantitatively in paraffin-fixed retinal cross sections. Biochemical alterations and the signal cascade in the retinas of DBA/2J mice in response to systemic injection of 17-beta-estradiol were also examined by reverse transcriptase PCR (RT-PCR) and western blot.

Results:: 17-beta-estradiol treatment reduced the loss of RGC and neurofibers through inhibition of ganglion cell apoptosis. 17-beta-estradiol activated Akt and cAMP-responsive-element-binding-protein (CREB), up-regulated thioredoxin-1 expression. 17-beta-estradiol suppressed the over-expressed interleukin-18 (IL-18) expression, reduced the increased activations of mitogen-activated protein kinases (MAPK) and NF-kB, and inhibited the elevated interleukin-18 expression in the retinas of DBA/2J mice. Pretreatment of tamoxifen, an estrogen receptor antagonist, can block 17-beta-estradiol-mediated activation of Akt and inhibition of MAPK phosphorylation in the retinas of DBA/2J mice.

Conclusions:: 17-beta-estradiol effectively slows the progression of IOP elevation and reduces retinal ganglion cell loss in DBA/2J mice. Multiple biochemical events including estrogen receptor/Akt/CREB/thioredoxin, and estrogen receptor/MAPK/NF-kB, may be involved in estrogen-mediated retinal ganglion cell protection.

Keywords: neuroprotection • ganglion cells • signal transduction 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×